Eli Lilly and Company (LLY) Expands Global Reach with Orforglipron Launch Plans in India

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Eli Lilly and Company is one of them.

Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best healthcare stocks. It is a global biopharmaceutical leader and continues to expand its presence across diabetes, obesity, oncology, immunology, and neurology. The company’s portfolio includes blockbuster drugs such as Mounjaro and Zepbound for diabetes and obesity, as well as donanemab for Alzheimer’s disease, supported by strong R&D capabilities and consistent commercial execution.

In September 2025, LLY announced plans for a $6.5 billion manufacturing facility in Houston, Texas, one of the city’s largest private investments in recent years. The site will expand production for small-molecule medicines, including orforglipron, its experimental oral GLP-1 receptor agonist for obesity. Expected to be operational within five years, the facility will create several hundred jobs while reinforcing LLY’s commitment to next-generation obesity treatments.

Eli Lilly and Company (NYSE:LLY) is also pursuing international growth, with plans to launch orforglipron in India pending regulatory approval. This move highlights the firm’s strategy to capture demand for oral weight-loss drugs in emerging markets. At the same time, the corporation streamlined its pipeline by halting development of a muscle-preserving drug paired with Zepbound, choosing to focus resources on its most promising obesity assets.

Meanwhile, LLY strengthened its neurology portfolio as European regulators granted marketing authorization for donanemab, advancing the business’s position in Alzheimer’s disease therapies. Financially, the firm reported strong international growth for Mounjaro, though U.S. sales were slightly impacted by isolated formulary challenges. Nevertheless, global demand for tirzepatide-based treatments remains robust, supporting an optimistic outlook for continued expansion.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.